p53 (TP53)
14, 57, 72, 107–109, 111, 112, 114, 117, 120–122, 127, 128, 158, 160
Paclitaxel
37–40, 42, 47, 48, 77, 78, 80, 83, 96, 101, 122–124, 147, 150, 151, 161
Paget’s Disease
22, 25, 35
Palbociclib
41, 43–46, 50
Palonosetron
52
Pap-Abstrich
104, 105, 140
PARP-Inhibitoren
14, 15, 47, 77, 78, 82–85, 122
Patient-reported Outcomes (PROs)
60
Pegfilgrastim
134
Pembrolizumab
38, 40, 47, 122, 123, 125, 146, 150, 151, 161, 168–170
Peritonealkarzinose
76, 81
Peritonealzytologie
73, 76, 95
Pertuzumab
38, 39, 42, 48, 50, 112
PET-CT
25, 26, 72, 105, 124, 140, 141, 144–146, 154, 158–160
Peutz-Jeghers-Syndrom
98
Phyllodes-Tumor
20, 34, 55
Pipelle
104, 105
Platinsensitivität
15, 80, 82, 83
Pneumonitis
35, 43, 47, 49, 50
POLE-Mutationsstatus
107–114, 115, 120–122
Polyembryom
95
Progesteron(rezeptor)
57, 88, 100, 103
Proliferationsmarker
57
ProMisE-Kriterien
107, 111, 112
Prosigna
58
Pseudomyxoma peritonei
72, 89
PTEN-Mutation
44, 103
QTc-Verlängerung
43, 50
